The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy
Top Cited Papers
- 25 November 2009
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 41 (4), 500-510
- https://doi.org/10.1002/mus.21544
Abstract
Walking abnormalities are prominent in Duchenne muscular dystrophy (DMD). We modified the 6‐minute walk test (6MWT) for use as an outcome measure in patients with DMD and evaluated its performance in 21 ambulatory boys with DMD and 34 healthy boys, ages 4 to 12 years. Boys with DMD were tested twice, ∼1 week apart; controls were tested once. The groups had similar age, height, and weight. All tests were completed. Boys who fell recovered rapidly from falls without injury. Mean ± SD [range] 6‐minute walk distance (6MWD) was lower in boys with DMD than in controls (366 ± 83 [125–481] m vs. 621 ± 68 [479–754] m; P < 0.0001; unpaired t‐test). Test‐retest correlation for boys with DMD was high (r = 0.91). Stride length (R2 = 0.89; P < 0.0001) was the major determinant of 6MWD for both boys with DMD and controls. A modified 6MWT is feasible and safe, documents disease‐related limitations on ambulation, is reproducible, and offers a new outcome measure for DMD natural history and therapeutic trials. Muscle Nerve, 2010Keywords
This publication has 33 references indexed in Scilit:
- Gait pattern in Duchenne muscular dystrophyGait & Posture, 2009
- T.P.5.01 Phase 2b Study of PTC124 in Duchenne/Becker muscular dystrophy (DMD/BMD): Demographic and other baseline dataNeuromuscular Disorders, 2008
- T.O.4 Safety and efficacy results from a randomized, double-blind, placebo-controlled study of alglucosidase alfa for the treatment of Pompe disease in juveniles and adultsNeuromuscular Disorders, 2008
- Verbal and memory skills in males with Duchenne muscular dystrophyDevelopmental Medicine and Child Neurology, 2007
- Challenges in drug development for muscle disease: A stakeholders' meetingMuscle & Nerve, 2006
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- Physical Activity, Health Impairments, and Disability in Neuromuscular DiseaseAmerican Journal of Physical Medicine & Rehabilitation, 2002
- Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophyPediatric Neurology, 1996
- Duchenne Muscular DystrophyAmerican Journal of Physical Medicine & Rehabilitation, 1995
- Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular DystrophyThe New England Journal of Medicine, 1989